Clinical Trial

Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-09-22; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2024-05-29
Trial Details
NCT Number NCT06053411
Lead Sponsor Washington State University
Conditions Interaction
Enrollment 30 participants
Start Date 2024-03-01
Primary Completion 2026-08-18 (estimated)
Study Completion 2026-12-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-04